Sugi Predict

Sugi Predict / Compounds / SCHEMBL5472147

SCHEMBL5472147

SCHEMBL5472147

CCOC(=O)c1n[nH]c2ccc(B3OC(C)(C)C(C)(C)O3)cc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.55
▸ POLB P06746 1/20 0.45
▸ PRMT5 O14744 2/20 0.43
▸ WDR77 Q9BQA1 2/20 0.43
▸ GSK3A P49840 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ HSD17B10 Q99714 3/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ NPC1 O15118 6/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPT P10636 5/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ HTT P42858 3/20 0.40
▸ LMNA P02545 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4794018 0.91 KDM4E (0.55) KDM4EPOLBPRMT5WDR77GSK3A
SCHEMBL4795214 0.84 KDM4E (0.50) KDM4EPOLBGSK3BHSD17B10KMT2A
SCHEMBL31725403 0.83 PRKAG1 (0.48) PRMT5WDR77GSK3AGSK3B
SCHEMBL4101185 0.76 KDM4E (0.68) KDM4EPOLBGSK3BHSD17B10KMT2A
SCHEMBL2997290 0.76 ALDH1A1 (0.46) KDM4EHSD17B10NPC1RAB9AALDH1A1
SCHEMBL12502513 0.76 JAK2 (0.46) KDM4EPRMT5WDR77GSK3AGSK3B
SCHEMBL1519972 0.76 PRMT5 (0.42) PRMT5WDR77GSK3AGSK3B
SCHEMBL30379604 0.76 PRMT5 (0.42) PRMT5WDR77GSK3AGSK3B
SCHEMBL31647457 0.76 ELANE (0.42) UCHL1
SCHEMBL5475399 0.75 PRMT5 (0.47) PRMT5WDR77GSK3AGSK3BHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263491-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC (US) 2025-08-21 — — US disclosed
US-20230120736-A1 ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES ABBVIE INC (US) 2023-04-20 — — US disclosed
US-20230114718-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC (US) 2023-04-13 — — US disclosed
US-20200338209-A1 ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES ABBVIE INC (US) 2020-10-29 — — US disclosed
CN-111620862-A BCL-XL-inhibitory compounds and antibody drug conjugates including the same 艾伯维公司 2020-09-04 — — CN disclosed
US-20200239553-A1 BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same ABBVIE INC. (US) 2020-07-30 — — US disclosed
US-20200147235-A1 ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES ABBVIE INC. 2020-05-14 — — US disclosed
US-20190153108-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC. (US) 2019-05-23 — — US disclosed
EP-3468599-A2 ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES AbbVie Inc. (US) 2019-04-17 — — EP disclosed
EP-3468616-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES AbbVie Inc. (US) 2019-04-17 — — EP disclosed
EP-3469000-A1 ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES AbbVie Inc. (US) 2019-04-17 — — EP disclosed
WO-2017214458-A2 ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES ABBVIE INC. (US) 2017-12-14 — — WO disclosed
WO-2017214301-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC. (US) 2017-12-14 — — WO disclosed
EP-3230283-A1 BCL-XL INHIBITORY COMPOUNDS AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME AbbVie Inc. (US) 2017-10-18 — — EP disclosed
WO-2016094517-A1 BCL-XL INHIBITORY COMPOUNDS AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME ABBVIE INC. (US) 2016-06-16 — — WO disclosed
US-20160158377-A1 BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same ABBVIE INC. (US) 2016-06-09 — — US disclosed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239553-A1 BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same BCL2, BCL2L10, BAX KDM4E 1090/4885POLB 3595/4885PRMT5 1883/4885
US-20230114718-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES EGFR, ERBB2, ERBB3 KDM4E 1013/4885POLB 3852/4885PRMT5 1773/4885
US-20200338209-A1 ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES HRH3, H1-3, CD274 KDM4E 424/4885POLB 4696/4885PRMT5 324/4885
US-20250263491-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES EGFR, ERBB2, ERBB3 KDM4E 1013/4885POLB 3852/4885PRMT5 1773/4885
US-20230120736-A1 ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES CD99, SLC3A2, CD63 KDM4E 2085/4885POLB 4155/4885PRMT5 2489/4885
US-20200147235-A1 ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES CD99, SLC3A2, CD63 KDM4E 2085/4885POLB 4155/4885PRMT5 2489/4885
US-20160158377-A1 BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same BCL2, BCL2L10, BAX KDM4E 1090/4885POLB 3595/4885PRMT5 1883/4885
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A KDM4E 2328/4885POLB 758/4885PRMT5 1026/4885
US-20190153108-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES EGFR, ERBB2, ERBB3 KDM4E 1013/4885POLB 3852/4885PRMT5 1773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.